PEPG
- PepGen Inc.
()
Overview
Company Summary
PepGen Inc. (PEPG) is a biotechnology company that specializes in developing innovative therapies for the treatment of neuromuscular diseases. The company focuses on utilizing nucleic acid medicines, specifically peptide nucleic acids (PNAs), to address genetic mutations that cause various genetic disorders.
PepGen's primary approach involves developing and optimizing PNAs, which are small synthetic molecules that can selectively bind to specific regions of RNA or DNA. By targeting these molecules to specific genetic targets, PEPG aims to modulate gene expression and correct the underlying genetic defects responsible for neuromuscular disorders.
The company's research and development efforts are centered on creating novel PNA designs and delivery platforms that can efficiently reach and modify the targeted genes. PepGen's innovative approach aims to overcome the challenges associated with traditional gene therapies, such as off-target effects and limited durability.
Additionally, PepGen collaborates with academic institutions, research organizations, and industry partners to advance its pipeline and expand its capabilities. The company is dedicated to bringing these potential therapeutic options to patients with currently untreatable genetic diseases, ultimately aiming to improve patient outcomes and quality of life.
Overall, PepGen Inc. focuses its operations on developing cutting-edge nucleic acid medicines, particularly PNAs, to address the genetic causes of neuromuscular diseases and provide potential breakthrough treatments for patients in need.